Cargando…

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update

Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease worldwide; it ranges from simple steatosis to steatohepatitis (NASH) and, potentially, cirrhosis and hepatocarcinoma. NAFLD is also an independent risk factor for type 2 diabetes, cardiovascular diseases, and morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Barchetta, Ilaria, Cimini, Flavia Agata, Cavallo, Maria Gisella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693133/
https://www.ncbi.nlm.nih.gov/pubmed/33126575
http://dx.doi.org/10.3390/nu12113302
_version_ 1783614673362354176
author Barchetta, Ilaria
Cimini, Flavia Agata
Cavallo, Maria Gisella
author_facet Barchetta, Ilaria
Cimini, Flavia Agata
Cavallo, Maria Gisella
author_sort Barchetta, Ilaria
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease worldwide; it ranges from simple steatosis to steatohepatitis (NASH) and, potentially, cirrhosis and hepatocarcinoma. NAFLD is also an independent risk factor for type 2 diabetes, cardiovascular diseases, and mortality. As it is largely associated with insulin resistance and related disorders, NAFLD has been recently re-named as Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD). At present, there are no approved pharmacological treatments for this condition. Vitamin D is a molecule with extensive anti-fibrotic, anti-inflammatory, and insulin-sensitizing properties, which have been proven also in hepatic cells and is involved in immune-metabolic pathways within the gut–adipose tissue–liver axis. Epidemiological data support a relationship hypovitaminosis D and the presence of NAFLD and steatohepatitis (NASH); however, results from vitamin D supplementation trials on liver outcomes are controversial. This narrative review provides an overview of the latest evidence on pathophysiological pathways connecting vitamin D to NAFLD, with emphasis on the effects of vitamin D treatment in MAFLD by a nonsystematic literature review of PubMed published clinical trials. This article conforms to the Scale for Assessment of Narrative Review Articles (SANRA) guidelines. Evidence so far available supports the hypothesis of potential benefits of vitamin D supplementation in selected populations of NAFLD patients, as those with shorter disease duration and mild to moderate liver damage.
format Online
Article
Text
id pubmed-7693133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76931332020-11-28 Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update Barchetta, Ilaria Cimini, Flavia Agata Cavallo, Maria Gisella Nutrients Review Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease worldwide; it ranges from simple steatosis to steatohepatitis (NASH) and, potentially, cirrhosis and hepatocarcinoma. NAFLD is also an independent risk factor for type 2 diabetes, cardiovascular diseases, and mortality. As it is largely associated with insulin resistance and related disorders, NAFLD has been recently re-named as Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD). At present, there are no approved pharmacological treatments for this condition. Vitamin D is a molecule with extensive anti-fibrotic, anti-inflammatory, and insulin-sensitizing properties, which have been proven also in hepatic cells and is involved in immune-metabolic pathways within the gut–adipose tissue–liver axis. Epidemiological data support a relationship hypovitaminosis D and the presence of NAFLD and steatohepatitis (NASH); however, results from vitamin D supplementation trials on liver outcomes are controversial. This narrative review provides an overview of the latest evidence on pathophysiological pathways connecting vitamin D to NAFLD, with emphasis on the effects of vitamin D treatment in MAFLD by a nonsystematic literature review of PubMed published clinical trials. This article conforms to the Scale for Assessment of Narrative Review Articles (SANRA) guidelines. Evidence so far available supports the hypothesis of potential benefits of vitamin D supplementation in selected populations of NAFLD patients, as those with shorter disease duration and mild to moderate liver damage. MDPI 2020-10-28 /pmc/articles/PMC7693133/ /pubmed/33126575 http://dx.doi.org/10.3390/nu12113302 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barchetta, Ilaria
Cimini, Flavia Agata
Cavallo, Maria Gisella
Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
title Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
title_full Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
title_fullStr Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
title_full_unstemmed Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
title_short Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
title_sort vitamin d and metabolic dysfunction-associated fatty liver disease (mafld): an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693133/
https://www.ncbi.nlm.nih.gov/pubmed/33126575
http://dx.doi.org/10.3390/nu12113302
work_keys_str_mv AT barchettailaria vitamindandmetabolicdysfunctionassociatedfattyliverdiseasemafldanupdate
AT ciminiflaviaagata vitamindandmetabolicdysfunctionassociatedfattyliverdiseasemafldanupdate
AT cavallomariagisella vitamindandmetabolicdysfunctionassociatedfattyliverdiseasemafldanupdate